Parkinsonian signs and substantia nigra neuron density in decendents elders without PD

Annals of Neurology

Volumn 56, Issue 4, 2004, Pages 532-539

  Ross, G Webster ^a,b,c,d,i   Petrovitch, Helen ^a,b,c,d   Abbott, Robert D ^b,e   Nelson, James ^b,d   Markesbery, William ^f   Davis, Daron ^f   Hardman, John ^d   Launer, Lenore ^g   Masaki, Kamal ^b,c,d   Tanner, Caroline M ^h   White, Lon R ^a,b,c  

^a Honolulu Dept of Veteran's Affairs   (United States)

^b PACIFIC HEALTH RESEARCH INSTITUTE   (United States)

^c KUAKINI MEDICAL CENTER   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h PARKINSON S INSTITUTE   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BODY POSTURE; BRADYKINESIA; BRAIN REGION; CELL DENSITY; CLINICAL FEATURE; CONTROLLED STUDY; FACIAL EXPRESSION; GAIT DISORDER; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; NERVE CELL; PARKINSON DISEASE; PRIORITY JOURNAL; SPEECH DISORDER; SUBSTANTIA NIGRA; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ASIAN AMERICANS; CELL COUNT; HUMANS; LEWY BODIES; MALE; NEURONS; PARKINSONIAN DISORDERS; POSTMORTEM CHANGES; SEVERITY OF ILLNESS INDEX; STAINING AND LABELING; SUBSTANTIA NIGRA;

EID: 4844226577     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20226     Document Type: Article

References (36)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
2. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
3. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-76.
4. Heilbrun LK, Kagan A, Nomura A, Wasnich RD. The origins of epidemiologic studies of heart disease, cancer and osteoporosis among Hawaii Japanese. Hawaii Med J 1985;44:294-296.
5. Kagan A, Harris BR, Winkelstein W Jr, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis 1974;27:345-364.
6. Yano K, Reed DM, McGee DL. Ten-year incidence of coronary heart disease in the Honolulu Heart Program: relationship to biologic and lifestyle characteristics. Am J Epidemiol 1984;119:653-666.
7. Morens DM, Davis JW, Grandinetti A, et al. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46:1044-1050.
8. White L, Petrovitch H, Ross GW, et al. Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-Asia Aging Study. JAMA 1996;276:955-960.
9. Petrovitch H, Nelson J, Snowdon D, et al. Microscope field size and the neuropathologic criteria for Alzheimer's disease. Neurology 1997;49:1175-1176.
10. Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990;53:245-249.
11. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000;283:2674-2679.
12. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 1994;6:45-58.
13. Fahn S, Elton RL, and members of the UPDRS development committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, eds. Recent developments in Parkinson's disease. Vol 2. New York: MacMillan, 1987:153-163.
14. Lane PW, Nelder JA. Analysis of covariance and standardization as instances of prediction. Biometrics 1982;38:613-621.
15. McCullagh P, Nelder JA. Generalized linear models. 2nd ed. London: Chapman and Hall, 1989:198-200.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. Washington, DC: American Psychiatric Association, 1987.
17. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, non-linear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43.
18. Prettyman R. Extrapyramidal signs in cognitively intact elderly people. Age Ageing 1998;27:557-560.
19. Richards M, Touchon J, Ledesert B, Ritchie K. Mild extrapyramidal signs and functional impairment in ageing. Int J Geriatr Psychiatry 2002;17:150-153.
20. Liu Y, Stern Y, Chun MR, et al. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997;41:368-374.
21. Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol Aging 2003;24:1-23.
22. Zarow C, Lyness SA, Mortimer JA, et al. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 2003;60:337-341.
23. Emborg ME, Ma SY, Mufson EJ, et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 1998;401:253-265.
24. Irwin I, DeLanney LE, McNeill T, et al. Aging and the nigro-striatal dopamine system: a non-human primate study. Neurodegeneration 1994;3:251-265.
25. Ma SY, Roytta M, Rinne JO, et al. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 1997;151:83-87.
26. Seibyl JP, Marek KL, Quinlan D, Gash DM. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
27. Booij J, Bergmans P, Winogrodzka A, et al. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001;39:101-108.
28. Jellinger KA. Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999;56:1-29.
29. Kish SJ, Shannak K, Rajput AH, et al. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 1992;58:642-648.
30. Newman RP, LeWitt PA, Jaffe M, et al. Motor function in the normal aging population: treatment with levodopa. Neurology 1985;35:571-573.
31. Grondin R, Zhang Z, Gerhardt GA, et al. Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys. Ann Neurol 2000;48:250-253.
32. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT. J Nucl Med 1995;36:1175-1181.
33. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122:1437-1448.
34. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122:1421-1436.
35. Hyman BT, Gomez-Isla T, Irizarry MC. Stereology: a practical primer for neuropathology. J Neuropathol Exp Neurol 1998;57:305-310.
36. Ma SY, Collan Y, Roytta M, et al. Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol 1995;21:10-17